SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Lab soars on launching Colesevelam HCI Tablets

10 Oct 2018 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2476.80, up by 30.20 points or 1.23% from its previous closing of Rs. 2446.60 on the BSE.

The scrip opened at Rs. 2480.00 and has touched a high and low of Rs. 2600.05 and Rs. 2450.50 respectively. So far 13150 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2687.45 on 28-Sep-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2600.05 and Rs. 2332.10 respectively. The current market cap of the company is Rs. 41112.12 crore.

The promoters holding in the company stood at 26.79 %, while Institutions and Non-Institutions held 44.27% and 14.60 % respectively.

Dr. Reddy’s Laboratories has launched Colesevelam HCI Tablets, USP, a therapeutic equivalent generic version of WELCHOL (colesevelam HCI) Tablets in the United States market approved by the US Food and Drug Administration (USFDA).

The WELCHOL brand and generic had US sales of around $471 million MAT for the most recent twelve months ending in August 2018 according to IMS Health. Dr. Reddy's Colesevelam Hydrochloride Tablets is available in 625 mg with 180 count bottle size.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Labs. Share Price

1374.55 28.30 (2.10%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: